Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tPA in Draining Chronic Subdural Hematomas
NCT05491356Phase 4Completed
- Sponsor
- Hamilton Health Sciences
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic subdural hematoma (CSDH) comparing Intervention - tPA administered with Placebo Control (2 arms). Primary endpoint: Study Feasibility at 8 months. Started May 2023; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT05491356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491356.